The effect of rosiglitazone in the treatment of autism

Phase 2

• Conditions: Autistic disorder.; Autistic disorder; F84.0

• Registration Number: IRCT20090117001556N150
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Diagnosis of autism based on DSM5 and ABC-C

Exclusion Criteria

Medically active disease
The presence of another psychological diagnosis in DSM 3 axis
History of previous sensitivity and intolerance to rosiglitazone
History of seizures and liver disorders
Taking antipsychotic drugs such as Risperidone before entering the study
Alanine aminotransferase (ALT) level < 2.5 at the beginning of the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of irritability. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).

Secondary Outcome Measures

Name	Time	Method
The severity of hyperactivity/noncompliance. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).;The severity of lethargy/social withdrawal. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).;The severity of stereotypic behavior. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).;The severity of inappropriate speech. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).